Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -50K | -2M | -2M | 0 | 0 |
| Operating Income | -4M | -9M | -6M | -39K | -21K |
| EBITDA | -5M | -10M | 0 | 156K | -21K |
| Net Income | -5M | -11M | -6M | -16K | -21K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PsyBio Therapeutics Corp. (PSYBF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +58.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +58.0%, free cash flow +50.5% with operating margin 0.0% and ROIC 328.6%. Stock Foundry combines PSYBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSYBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PSYBF Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PSYBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$20.9K
-29.1% YoY
Free Cash Flow
-$13.9K
+42.3% YoY
Revenue Growth
+0.0%
EPS Growth
+58.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -50K | -2M | -2M | 0 | 0 |
| Operating Income | -4M | -9M | -6M | -39K | -21K |
| EBITDA | -5M | -10M | 0 | 156K | -21K |
| Net Income | -5M | -11M | -6M | -16K | -21K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 848 | 124K | 270K | 162K | 194K |
| Total Assets | 390K | 4M | 286K | 162K | 194K |
| Total Liabilities | 2M | 1M | 1M | 34K | 43K |
| Shareholder Equity | -2M | 3M | -737K | 128K | 150K |
| Total Debt | 135K | 0 | 0 | 0 | 0 |
| Net Debt | 135K | -124K | -270K | -162K | -194K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14K
+42.3% YoY
Capital Expenditures
0
Free Cash Flow
14K
+42.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-867.3%
Debt / Equity
-0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.